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A major challenge in biology is the discovery of the
processes controlled by the roughly one-third of
genes with no known function. One approach being
explored to address this problem is the use of small
molecules in conjunction with genetics—chemical
genetics. A short review of this field is provided as
an introduction to a series of papers in this issue of
Cell in which a new type of chemical genetics re-
vealed the function of a new outer membrane protein
complex in bacteria.
Genetics is the dominant tool and paradigm for under-
standing biology. However, there are limitations to the
power of genetics. Even though E. coli has been geneti-
cally manipulatable for over 50 years, about one-third
of E. coli genes have no known function. Why have mu-
tations in these genes failed to provide us with a clue
as to their function? Do these genes encode missing
pieces of known cellular machinery, or do some work
together with other genes of unknown function in yet
undiscovered molecular machines? The field of chemi-
cal biology is playing an increasingly prominent role in
biology. Here I will attempt to motivate the need for de-
veloping approaches that utilize both chemical and ge-
netic tools for studying biological systems. I will intro-
duce the four typical “formats” for so-called chemical
genetic experiments in the context of traditional genet-
ics and pharmacology. With this as a background, I will
summarize the findings described in two articles, in this
issue of Cell, that use a new format for chemical genet-
ics to probe antibiotic resistance and membrane bio-
genesis in E. coli, revealing a new outer membrane
(OM) machine composed of four proteins of previously
unknown function (Ruiz et al., 2005; Wu et al., 2005).
In the sections below I will attempt to define the two
pillars of chemical genetic methods: genetics and phar-
macology.
Genetics
Specific mutations can be introduced into cells or or-
ganisms providing a highly specific perturbation to
complex systems. However, perturbations made to
DNA or RNA are translated slowly into changes at the
protein level (days for RNAi and weeks in the case of
mouse genetics). Rapidly evolvable systems that can
adapt to compensate for missing components, such as
signal-transduction pathways, can be difficult to study
without the means to rapidly perturb the system. Ge-*Correspondence: shokat@cmp.ucsf.edunetics is specific but perturbs the system slowly—
allowing the system to compensate.
Pharmacology
Pharmacological agents would appear to be an ideal
complement to the shortfalls of genetic tools. Highly
selective and potent inhibitors of single proteins are
powerful tools for complementing genetic studies be-
cause they allow the study of essential proteins and
they inhibit their targets rapidly and reversibly (seconds
to minutes). The limitation of pharmacology is the rela-
tively small number of molecules with optimal proper-
ties of unique specificity and potency compared to the
diversity of potential target proteins in biology. Ad-
vances in organic synthesis, structural biology, and
high-throughput screening have greatly accelerated the
process of small molecule tool and drug discovery, yet
few such molecules have specificity that approaches
that of genetics. Small molecules act rapidly but are
often pleiotropic.
Chemical Genetics
Chemical diversity is at the heart of both genetics and
pharmacology. Changes to DNA or small molecule
structure control biological function. In the case of
chemistry, we refer to the diversity of structures. In the
case of genetics, we refer to sequence variation.
Hence, diversity serves as a common benchmark for
classifying chemical and genetic methods to study bi-
ology (Figure 1). The intersection points of chemical or
genetic approaches categorize chemical genetic ap-
proaches for probing biology. In the first column of Fig-
ure 1, traditional genetics can be categorized as re-
verse genetics (Figure 1D) or forward genetics (Figure
1G) depending on whether a directed mutation is made
or whether mutants are obtained by selections or
screens. Similarly, pharmacology typically utilizes a
small number of known bioactive small molecules to
perturb a biological system (Figure 1B).
With these genetic and pharmacological approaches
as benchmarks, we can focus on the classification of
chemical genetic approaches to the study of biology. If
a complex set of small molecules are screened in order
to identify new pharmacological agents, the chemicals
used to perturb the biological system can be viewed
as the functional equivalent of point mutations. Thus,
screening through a library of small molecules can be
thought of as a forward chemical genetic screen (Figure
1C). Monastrol, an inhibitor of the mitotic kinesin motor,
Eg5, was discovered in this assay format (Mayer et al.,
1999). Small molecules that induce stem-cell differenti-
ation to cardiomyocytes have been discovered in the
same format (Wu et al., 2004). When this same chemical
diversity is applied to a screen in which a “normal” and
a “mutant” cell are screened in parallel to search for a
mutant-specific inhibitor, one can envision a screen for
anticancer agents. Screening compound libraries in the
NCI-60 cancer cell line panel is an example of this
chemical genetic format (Figure 1F) (Holbeck, 2004). In
these two formats of chemical genetic experiments, the
challenge is the production of large numbers of poten-
tially biologically active small molecules and the dis-
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164Figure 1. Classification of Chemical and Ge-
netic Methods to Study Biologycovery of the cellular targets of “hit” molecules (Bur-
mdine and Kodadek, 2004). The challenge of small
molecule target identification points out a key distinc- c
dtion between forward chemical genetic and forward ge-
netic screens: the mutation can easily be recovered af- s
pterwards whereas the small molecule target cannot.
A more hypothesis-based experimental format for g
wchemical genetic experiments has also become quite
useful. If information about a protein in the pathway or a
hprocess of interest is known, a more targeted approach
can be used to discover selective small molecules. For a
mexample, if a specific protein kinase is implicated in a
given pathway, a highly specific small molecule inhibi- c
2tor for the protein kinase of interest can be readily gen-
erated using the chemical genetic format in Figure 1E
s(Bishop et al., 2000b). In this experiment, a point muta-
tion is made in the ATP binding pocket of interest, ren- s
udering only this mutant kinase sensitive to a designed
small molecule inhibitor that does not inhibit any wild- b
ctype protein kinases (an allele-specific inhibitor). This
form of reverse chemical genetics is powerful in terms b
Iof the ability to target a single enzyme in a large family
even if the active site is highly conserved, precluding h
tuse of traditional medicinal chemistry to develop a
highly specific inhibitor (Bishop et al., 2000a). In this b
sformat the target is thus under genetic control provid-
ing high specificity and pharmacological control con- v
aferring rapid regulation.The issue of the true molecular target(s) of a small
olecule is a recurring challenge to the field of chemi-
al biology as well as pharmacology. Without real un-
erstanding of the target, it is difficult to integrate re-
ults produced by chemicals into cellular pathways and
rocesses. One of the most exciting areas of chemical
enetics is the combination of pharmacology and for-
ard genetic screens to identify the cellular targets of
ctive small molecules (Figure 1H). A flurry of papers
ave applied various formats to identify mutants that
re hypersensitive to pharmacologically active small
olecules using happloinsufficiency or gene-deletion
ollections (Deutschbauer et al., 2005; Parsons et al.,
004, Lum et al., 2004).
Enter Kahne and Silhavy, whose labs have been
earching for the specific cellular target(s) of a very
tructurally complex natural product, vancomycin (Fig-
re 2). This antibiotic is chemically complex with a
inding site for a dipeptide component of the bacterial
ell wall as well as sugars that target another class of
acterial cell wall components, glycosyl transferases.
n fact, its many characterized biochemical activities
ave led to conflicting hypotheses about the “real”
arget of the antibiotic. In a classic pharmacology-
ased effort to separate the activities of vancomycin,
ynthetic versions of vancomycin, like chlorobiphenyl
ancomycin (CBP-vanco), were made in order to dam-
ge some properties (dipeptide binding) and preserve
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165Figure 2. Continuum of Outer Membrane Mutants that Suppress the Toxicity of Small Molecules
Bile salts (top left) at one end of the continuum are suppressed by a variety of outer membrane mutants (bottom left). Vancomycin (top right)
at the other end of the continuum is only suppressed by a mutation that also suppresses sensitivity to compounds to the left. CBP-vanco
and yfgL lie in the middle.or enhance others (glycosyl transferase inhibition) (Ge
et al., 1999). As a test of the formal understanding of
the mechanism of these designer vancomycin analogs,
Kahne and Silhavy used each as the basis for a forward
genetic screen for mutants that could resist the antibi-
otic action of CBP-vanco, hoping to identify mutations
in a specific enzyme target of this antibiotic (Eggert et
al., 2001). The initial goal was to resolve a controversy
about the mechanism of action of vancomycin and sev-
eral vancomycin analogs—do they kill bacteria by inhi-
bition of glycosyltransferases or by binding to peptido-
gylcan intermediates in the membrane?
When cells were challenged with CBP-vanco, the
chemical conditionality screen retrieved only mutations
in an unannotated gene, yfgL (Ruiz et al., 2005 [this is-
sue of Cell]). Prior to this screen for chemically condi-
tional growth, no forward genetic selection or screen
had identified mutations in this gene. How had a chemi-
cal genetic screen retrieved a mutant that could not be
identified by genetics alone? To answer this question,
Kahne and Silhavy expanded the chemical genetic
screen to include a series of drug controls including
vancomycin itself and molecules, such as bile salts (the
red molecule in Figure 2), generally toxic to bacteria
that are not structurally or functionally related to CBP-
vanco. These studies showed that YfgL is not the ac-
tual target of CBP-vancomycin, but that yfgL lies on a
continuum of mutations that can suppress the effects
of various antibiotics. This continuum of sensitivity of
the various mutant strains is only revealed by the use of
structurally diverse molecules—provided by chemistry
(Figure 2).The first big “take-home message” from the chemical
genetic screening perspective is that compounds of
different structure and target class (vancomycin deriva-
tives versus bile salts) can classify mutant strains ac-
cording to their ability to be toxic. Without the com-
pounds, these mutants would all be characterized as
having a “leaky” membrane revealing little about their
function or differential effects.
In the second paper in the series (Wu et al., 2005
[this issue of Cell]), the authors turned to answer the
question why had the screen returned molecules in the
OM of bacteria? To answer this question, they used the
single gene, yfgL, discovered in the chemical genetic
screen as a foothold into studying the OM function of
YfgL. Through immunoprecipitation studies, YfgL was
found to be part of a multiprotein complex in the OM
that is essential for biogenesis of the OM. Moreover,
this protein complex is composed of the products of
three other genes of unknown function, yaeT, yfiO,
and nlpB.
The second lesson from this study is the finding that
chemical genetics has led to the identification of four
proteins of unknown function operating together in a
complex, a completely unknown OM machine. This
suggests the exciting possibility that uncovering the
function of unknown proteins may lead to entirely new
cellular machines for study. Kahne and Silhavy point
out some of the most interesting aspects of the func-
tion of this new complex in the context of OM biogene-
sis. The OM is an organelle that assembles outside the
bacterial cell wall (the peptidoglycan layer)—and thus
assembles in the absence of any discernible energy
Cell
166Bsource (ATP). They show that perturbing or removing
Aone of the proteins perturbs the ability of the complex
Mto assemble proteins in the OM. A speculative model is
Sthat the cell carefully balances the assembly of the pro-
Ptein and lipid components of the OM to precisely con-
B
trol the barrier function of this organelle. An obvious N
way for the cell to tightly couple expression of multiple
R
genes is to regulate their expression by the same tran- t
scription factor. In fact, Carol Gross’s lab has recently W
found that the genes encoding components of the (
same OM machine are in the sigmaE regulon, which W
is necessary for responding to cell envelope stress (C. A
Gross, personal Communication).
What lessons do these papers provide for future
chemical genetic studies? A particularly surprising les-
son to me was the utility of a molecule to probe some
aspect of cell function other than the actual “target” of
the small molecule, i.e., the enzyme active site. Tradi-
tional pharmacology teaches us to think of inhibitors as
binding to an active site, lock and key, but we forget
that molecules must pass through cellular membranes
and may do so through interaction with specific protein
or lipid components. Thus small molecules can be used
to probe these membrane-proximal events and give in-
sight into machines in the membrane that may have
eluded study with genetics alone.
Finally, biology is not simply DNA-RNA-protein, but
small molecules are intimate components and sub-
strates for natural evolution (Figure 1I). Thus, many of
the proteins and molecular machines we study in biol-
ogy are designed to be regulated by naturally occurring
small molecules (nucleotides, cofactors, lipids, etc.).
Therefore it stands to reason that we must use small
molecule tools to appropriately and completely study
the machines in order to better understand biology
(Clardy and Walsh, 2004).
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